Pomalidomide

Generic Name: Pomalidomide

Brand Names: Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₁N_₃O_₄

CAS Number: 19171-19-8

Unique Ingredient Identifier: D2UX06XLB5

Background: Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

Indication: Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.

Associated Conditions: Kaposi's Sarcoma, Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: GSK3174998
Drug: Feladilimab
Drug: Nirogacestat
Drug: Dostarlimab
Drug: Isatuximab
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Pomalidomide

First Posted Date: 2019-10-15

Last Posted Date: 2025-01-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 209

Registration Number: NCT04126200

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

Phase 2

Active, not recruiting

Conditions: Deletion 17P Syndrome
Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2019-10-11

Last Posted Date: 2024-07-22

Lead Sponsor: Fondazione EMN Italy Onlus

Target Recruit Count: 45

Registration Number: NCT04124497

Locations: 🇮🇹
Ospedali Riuniti, Bergamo, Italy
🇮🇹
Istituto Clinico Humanitas, Rozzano, Italy
🇮🇹
Policlinico Universitario di Udine, Udine, Italy

and more 12 locations

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Talquetamab
Drug: Teclistamab
Drug: Pomalidomide

First Posted Date: 2019-09-30

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 290

Registration Number: NCT04108195

Locations: 🇨🇦
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States

and more 21 locations

Ixazomib + Pomalidomide + Dexamethasone In MM

Phase 1

Recruiting

Conditions: Multiple Myeloma
Multiple Myeloma in Relapse

Interventions: Drug: Ixazomib
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2019-09-19

Last Posted Date: 2024-03-12

Lead Sponsor: Omar Nadeem, MD

Target Recruit Count: 61

Registration Number: NCT04094961

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study to Evaluate CCS1477 in Haematological Malignancies

Phase 1

Recruiting

Conditions: Non Hodgkin Lymphoma
Haematological Malignancy
Acute Myeloid Leukemia
Higher-risk Myelodysplastic Syndrome
Multiple Myeloma
Peripheral T Cell Lymphoma

Interventions: Drug: CCS1477
Drug: Pomalidomide
Drug: Azacitidine
Drug: Dexamethasone
Drug: Venetoclax

First Posted Date: 2019-08-28

Last Posted Date: 2024-03-15

Lead Sponsor: CellCentric Ltd.

Target Recruit Count: 250

Registration Number: NCT04068597

Locations: 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇬🇧
The Royal Marsden, Sutton, Surrey, United Kingdom
🇫🇷
Institute Gustave Roussy, Villejuif, France

and more 12 locations

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: isatuximab SAR650984 IV
Drug: pomalidomide
Drug: isatuximab SAR650984 SC
Drug: dexamethasone
Device: Investigational injector device

First Posted Date: 2019-08-06

Last Posted Date: 2024-04-29

Lead Sponsor: Sanofi

Target Recruit Count: 56

Registration Number: NCT04045795

Locations: 🇦🇺
Investigational Site Number : 0360004, Fitzroy, Victoria, Australia
🇺🇸
~Banner MD Anderson Cancer Center Site Number : 8400005, Gilbert, Arizona, United States
🇯🇵
Investigational Site Number : 3920002, Okayama-shi, Okayama, Japan

and more 11 locations

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: TAK-079
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Bortezomib
Drug: Pomalidomide

First Posted Date: 2019-06-12

Last Posted Date: 2024-04-30

Lead Sponsor: Takeda

Target Recruit Count: 50

Registration Number: NCT03984097

Locations: 🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Pacific Cancer Care, Monterey, California, United States

and more 6 locations

A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders

Phase 2

Completed

Conditions: Amyloidosis
Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Lenalidomide

First Posted Date: 2019-05-22

Last Posted Date: 2023-07-24

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 10

Registration Number: NCT03959358

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 2

Withdrawn

Conditions: Recurrent Plasma Cell Myeloma

Interventions: Biological: Daratumumab
Drug: Dexamethasone
Drug: Pomalidomide

First Posted Date: 2019-02-15

Last Posted Date: 2022-06-15

Lead Sponsor: Academic and Community Cancer Research United

Registration Number: NCT03841565

Locations: 🇺🇸
Cancer Center of Kansas - Wichita, Wichita, Kansas, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
State University of New York Upstate Medical University, Syracuse, New York, United States

and more 2 locations

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Bortezomib
Drug: Dexamethasone
Drug: Pomalidomide

First Posted Date: 2019-02-04

Last Posted Date: 2023-11-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 15

Registration Number: NCT03828292

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy